CryoPort Stock (NASDAQ:CYRX), Trade Ideas

CryoPort

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

CYRX

HEAR

HOOD

LQDA

PERF

PLMR

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Thursday.

Build-A-Bear Workshop Reports Upbeat Earnings, Joins VAALCO Energy, Dick&#39;s Sporting Goods And Other Big Stocks Moving Higher On Thursday

Analyst Color

Equities

Downgrades

Analyst Ratings

General

KeyBanc Capital Markets analyst Paul Knight downgraded CryoPort, Inc (NASDAQ: CYRX) to 

CryoPort&#39;s Refrigeration Unit Is A Distraction From Core Business: Analyst Expects Divestiture

Earnings

Guidance

Health Care

Price Target

AZTA

Cryoport Inc (NASDAQ: CYRX) shares are trading lower after the company released certain preliminary results for Q2 FY23 and updated its

Cryoport On See-Saw Of Expectations: Analysts Cut Price Targets, But Remain Bullish On Long-Term Return

CryoPort Inc

5 analysts have shared their evaluations of CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CryoPort, revealing an average target of $18.4, a high estimate of $21.00, and a low estimate of $17.00. Observing a 7.48% increase, the current average has risen from the previous average price target of $17.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1712239247_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive CryoPort is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Stanton</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$14.50</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CryoPort. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CryoPort's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CryoPort's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into CryoPort's Background</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>Key Indicators: CryoPort's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: CryoPort's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -5.13%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CryoPort's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -112.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CryoPort's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.19%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -6.58%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.9, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing CryoPort: Insights From 5 Financial Analysts

Jefferies analyst Matthew Stanton assumes CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy rating and raises Price Target to $21.

Initiation

Jefferies Assumes CryoPort at Buy, Raises Price Target to $21

4 analysts have expressed a variety of opinions on CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.75, a high estimate of $19.00, and a low estimate of $17.00. This current average has increased by 3.38% from the previous average price target of $17.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1710511230_0_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of CryoPort's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$14.50</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CryoPort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CryoPort's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into CryoPort's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>Key Indicators: CryoPort's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, CryoPort faced challenges, resulting in a decline of approximately -5.13% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CryoPort's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -112.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CryoPort's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -13.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -6.58%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.9, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For CryoPort

UBS analyst John Sourbeer maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Neutral and raises the price target from $14.5 to $17.

UBS Maintains Neutral on CryoPort, Raises Price Target to $17

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Thursday.
Shares of Build-A-Bear Workshop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbw#NYSE">BBW</a>) rose sharply during Thursday&rsquo;s session after the company reported better-than-expected fourth-quarter EPS but missed on revenue, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Additionally, the company guided FY24 revenue growth on a low-to-mid-single-digit <a href="https://www.benzinga.com/quote/BBW/earnings">percentage basis</a>.
Build-A-Bear Workshop shares jumped 15.7% to $29.20 on Thursday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Turtle Beach Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hear#NASDAQ">HEAR</a>) shares surged 29.2% to $14.25 after the company announced the acquisition of PDP and its intention to launch a modified &quot;Dutch Auction&quot; Tender Offer. The company also reported fourth-quarter financial results.</li>
<li>VAALCO Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/egy#NYSE">EGY</a>) shares climbed 22% to $5.45 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>DICK&#39;S Sporting Goods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dks#NYSE">DKS</a>) gained 14.8% to $215.70 after the company reported strong fourth-quarter results and issued guidance above consensus estimates.</li>
<li>Lithium Americas Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lac#NYSE">LAC</a>) climbed 14.6% to $6.57 after the company announced that it received a conditional commitment from the U.S. Department of Energy for a $2.26 billion loan under the Advanced Technology Vehicles Manufacturing Loan Program for financing the construction of the processing facilities at Thacker Pass in Nevada.</li>
<li>Impinj, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pi#NASDAQ">PI</a>) rose 11.5% to $126.53 after the company announced a patent litigation settlement with NXP Semiconductors.</li>
<li>Palomar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plmr#NASDAQ">PLMR</a>) gained 9.4% to $83.24. Jefferies analyst Andrew Andersen upgraded Palomar from Hold to Buy and raised the price target from $78 to $88.</li>
<li>Eventbrite, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eb#NYSE">EB</a>) rose 8.7% to $5.55. Eventbrite announced a $100 million share repurchase program.</li>
<li>Perfect Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/perf#NYSE">PERF</a>) climbed 8.6% to $2.8550.</li>
<li>Liquidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) surged 8.5% to $15.98.</li>
<li>IHS Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihs#NYSE">IHS</a>) gained 7.7% to $3.05. TD Cowen analyst Gregory Williams maintained IHS Holding with an Outperform and lowered the price target from $19 to $15.</li>
<li>Robinhood Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) gained 6.3% to $18.24 after the company reported February trading metrics.</li>
<li>Cryoport, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyrx#NASDAQ">CYRX</a>) gained 6.1% to $15.24. CryoPort recently reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) gained 5.7% to $7.79.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37699845/nerdy-and-3-other-stocks-under-3-insiders-are-buying"> Nerdy And 3 Other Stocks Under $3 Insiders Are Buying</a>

Build-A-Bear Workshop Reports Upbeat Earnings, Joins VAALCO Energy, Dick's Sporting Goods And Other Big Stocks Moving Higher On Thursday

Stephens &amp; Co. analyst Jacob Johnson reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Equal-Weight and maintains $17 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on CryoPort, Maintains $17 Price Target

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. The market value of their outstanding shares is at $42.7 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock moved upwards by 25.0% to $0.1. The market value of their outstanding shares is at $4.0 million. </li>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) stock moved upwards by 19.34% to $0.87. The company's market cap stands at $2.5 million. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock moved upwards by 14.97% to $2.38. The company's market cap stands at $303.4 million. </li>
<li>HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) stock increased by 14.04% to $18.62. The company's market cap stands at $3.1 billion. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares rose 13.14% to $0.62. The market value of their outstanding shares is at $22.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) shares decreased by 14.7% to $0.87 during Wednesday's pre-market session. The market value of their outstanding shares is at $100.2 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 12.69% to $3.51. The market value of their outstanding shares is at $2.5 million. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares decreased by 10.39% to $14.61. The market value of their outstanding shares is at $715.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock fell 9.9% to $0.82. The company's market cap stands at $40.9 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares declined by 8.57% to $5.39. The market value of their outstanding shares is at $117.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 8.21% to $0.04. The company's market cap stands at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGRX

ATNF

CELU

CMPX

Kintara Therapeutics, Inc. - Common Stock

KTRA

NCNA

PIII

RNLX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

CryoPort shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY24 revenue guidance below estimates.

Needham analyst David Saxon maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and lowers the price target from $19 to $18.

Needham Maintains Buy on CryoPort, Lowers Price Target to $18

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock rose 157.2% to $0.99 during Tuesday's after-market session. The market value of their outstanding shares is at $52.2 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) stock moved upwards by 39.54% to $0.77. The company's market cap stands at $27.4 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares moved upwards by 20.19% to $0.5. The market value of their outstanding shares is at $3.6 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) stock rose 14.56% to $1.73. The company's market cap stands at $4.2 million. As per the press release, Q4 earnings came out today. </li>
<li>MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) shares increased by 14.0% to $4.54. The company's market cap stands at $469.9 million. As per the press release, Q4 earnings came out today. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares rose 13.29% to $4.61. The market value of their outstanding shares is at $2.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 13.9% to $3.46 during Tuesday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 11.85% to $0.04. The market value of their outstanding shares is at $1.1 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock declined by 11.61% to $0.9. The company's market cap stands at $103.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 10.74% to $1.83. The market value of their outstanding shares is at $2.2 million. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock declined by 9.51% to $14.75. The company's market cap stands at $722.2 million. The company's, Q4 earnings came out today. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock decreased by 8.97% to $0.48. The company's market cap stands at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

MXCT

SCNI

TNON

WORX

12 Health Care Stocks Moving In Tuesday's After-Market Session

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
CryoPort missed estimated earnings by -3.0%, reporting an EPS of $-0.3 versus an estimate of $-0.29.
Revenue was down $3.10 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 10.0% increase in the share price the next day.
Here's a look at CryoPort's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-0.24</td>
<td>-0.19</td>
<td>-0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.31</td>
<td>-0.42</td>
<td>-0.16</td>
<td>-0.24</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>55.27M</td>
<td>59.36M</td>
<td>62.15M</td>
<td>58.27M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>56.16M</td>
<td>57.02M</td>
<td>62.82M</td>
<td>60.36M</td>
</tr>
</tbody>
</table>

To track all earnings releases for CryoPort <a href="https://www.benzinga.com/quote/CYRX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: CryoPort Q4 Earnings

CryoPort Sees FY24 Revenue $242M-$252M vs $253.22M Est.

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.30) by 336.67 percent. The company reported quarterly sales of $57.260 million which missed the analyst consensus estimate of $58.396 million by 1.94 percent. This is a 5.13 percent decrease over sales of $60.358 million the same period last year.

Earnings Misses

CryoPort Q4 2023 GAAP EPS $(1.31) Misses $(0.30) Estimate, Sales $57.260M Miss $58.396M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is likely to report earnings for its fourth quarter.
&bull; MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $530.30 million.
&bull; BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) is likely to report quarterly loss at $0.91 per share on revenue of $710 thousand.
&bull; Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $45.27 million.
&bull; Tupperware Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) is estimated to report earnings for its second quarter.
&bull; Kanzhun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $214.08 million.
&bull; Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) is projected to report quarterly loss at $0.22 per share on revenue of $222.43 million.
&bull; FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $34.53 million.
&bull; Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) is projected to report quarterly earnings at $1.43 per share on revenue of $23.64 billion.
&bull; On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $510.19 million.
&bull; Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is projected to report quarterly earnings at $0.51 per share on revenue of $16.09 million.
&bull; Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $-250 thousand.
&bull; Kohl&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is estimated to report quarterly earnings at $1.28 per share on revenue of $5.70 billion.
&bull; PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWFL#NASDAQ">PWFL</a>) is likely to report quarterly loss at $0.10 per share on revenue of $34.34 million.
&bull; Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $197.93 million.
&bull; IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $476.18 million.
&bull; Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $123.96 million.
&bull; Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.24 million.
&bull; Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly loss at $0.10 per share on revenue of $201.84 million.
&bull; Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) is estimated to report earnings for its fourth quarter.
&bull; Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $245.27 million.
&bull; ATRenew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NYSE">RERE</a>) is projected to report earnings for its fourth quarter.
&bull; Core Molding Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMT#AMEX">CMT</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $70.75 million.
&bull; Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) is projected to report quarterly earnings at $0.41 per share on revenue of $1.11 billion.
&bull; Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is projected to report quarterly loss at $0.13 per share on revenue of $48.40 million.
<h3>Companies Reporting After The Bell</h3>
&bull; ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $6.53 million.
&bull; Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $172.68 million.
&bull; MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $13.09 million.
&bull; Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $111.13 million.
&bull; Performant Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFMT#NASDAQ">PFMT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $31.59 million.
&bull; Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $0.98 per share on revenue of $592.58 million.
&bull; Arq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQ#NASDAQ">ARQ</a>) is likely to report quarterly loss at $0.08 per share on revenue of $27.00 million.
&bull; Rackspace Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) is projected to report quarterly loss at $0.04 per share on revenue of $714.72 million.
&bull; Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $45.74 million.
&bull; Intl General Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) is likely to report earnings for its fourth quarter.
&bull; Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) is projected to report quarterly loss at $0.15 per share on revenue of $13.48 million.
&bull; Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) is projected to report quarterly loss at $0.27 per share on revenue of $1.60 million.
&bull; Surgepays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $33.52 million.
&bull; Maiden Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHLD#NASDAQ">MHLD</a>) is likely to report earnings for its fourth quarter.
&bull; SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) is likely to report earnings for its fourth quarter.
&bull; Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) is projected to report quarterly loss at $2.00 per share on revenue of $2.10 million.
&bull; Doma Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOMA#NYSE">DOMA</a>) is likely to report quarterly loss at $1.30 per share on revenue of $69.42 million.
&bull; Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.07 per share on revenue of $87.63 million.
&bull; Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $8.74 million.
&bull; Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is projected to report quarterly loss at $0.13 per share on revenue of $29.34 million.
&bull; Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $4.43 million.
&bull; Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) is expected to report quarterly loss at $0.16 per share on revenue of $30.97 million.
&bull; AdTheorent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTH#NASDAQ">ADTH</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $56.20 million.
&bull; Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) is likely to report quarterly loss at $0.03 per share on revenue of $30.00 million.
&bull; Oportun Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $262.30 million.
&bull; icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is likely to report quarterly loss at $0.05 per share on revenue of $4.30 million.
&bull; Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.18 per share on revenue of $145.56 million.
&bull; Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $73.07 million.
&bull; Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is likely to report quarterly loss at $1.38 per share on revenue of $1.06 million.
&bull; Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.03 per share on revenue of $13.60 million.
&bull; loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $236.76 million.
&bull; CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is estimated to report quarterly loss at $0.29 per share on revenue of $58.40 million.
&bull; Synchronoss Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) is likely to report quarterly loss at $0.10 per share on revenue of $42.84 million.
&bull; Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $480.25 million.
&bull; Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $226.02 million.
&bull; Eastern Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EML#NASDAQ">EML</a>) is likely to report earnings for its fourth quarter.
&bull; BRT Apartments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRT#NYSE">BRT</a>) is estimated to report earnings for its fourth quarter.
&bull; Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is expected to report quarterly loss at $0.06 per share on revenue of $87.21 million.
&bull; Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is likely to report quarterly loss at $0.11 per share on revenue of $151.50 million.
&bull; Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) is projected to report quarterly loss at $0.23 per share on revenue of $69.06 million.
&bull; Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $47.25 million.
&bull; PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $9.37 million.
&bull; Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is likely to report quarterly loss at $0.15 per share on revenue of $33.79 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ADTH

ALGS

ATER

AWRE

BIRD

BLDE

BTAI

BTMD

CLOV

CLPT

CLSD

CRMD

CSBR

DOMA

ENFN

GHLD

HGTY

HRTX

ICAD

IGIC

INVE

LCUT

MANU

MHLD

MNSO

NATR

NOTE

NRGV

ONON

OPRT

PFMT

PHUN

PRPL

PRTH

PWFL

QFIN

QRHC

REFI

RERE

SIGA

SKIN

SNCR

SURG

SWIM

TACT

VERI

WEST

WKHS

Earnings Scheduled For March 12, 2024

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-12. Here's what investors need to know before the announcement.
Analysts estimate that CryoPort will report an earnings per share (EPS) of $-0.29. 
CryoPort bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 10.03% increase in the share price the next day.
Here's a look at CryoPort's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-0.24</td>
<td>-0.19</td>
<td>-0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.31</td>
<td>-0.42</td>
<td>-0.16</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-2.0%</td>
<td>14.000000000000002%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710165757_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of CryoPort were trading at $16.85 as of March 08. Over the last 52-week period, shares are down 21.85%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CYRX/earnings">To track all earnings releases for CryoPort visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: CryoPort

Needham analyst David Saxon maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and raises the price target from $18 to $19.

Needham Maintains Buy on CryoPort, Raises Price Target to $19

Companies Will Partner to Provide Complete Supply Chain Solutions for the&nbsp;Life Science and Biopharmaceutical Industries
NASHVILLE, Tenn., Nov. 27, 2023 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4032781-1&amp;h=4044154370&amp;u=https%3A%2F%2Fcyrx.co%2F3sJdiZ6&amp;a=Cryoport">Cryoport</a>&nbsp;Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and NIPPON EXPRESS HOLDINGS, INC. ("Nippon Express"), global logistics company, today announced a strategic partnership to provide temperature-controlled supply chain services for the life sciences industry on a global basis.
Cryoport and Nippon Express will partner to design and implement comprehensive supply chain solutions to support each other's business efforts. The partnership will cover globally. This relationship brings together Nippon Express' industry-leading global logistics, with Cryoport Systems' fully integrated system, processes and equipment including its shipping packages, data solutions, biostorage and bioservices, and the ability to provide complete cell and gene therapy support services from upstream biomaterial collection to final delivery for dosing.
Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "This partnership builds on our growing presence globally and bolsters our ability to service customers by benefiting from Nippon Express' industry-leading global network. As an organization, Cryoport is committed to enhancing its logistics solutions and adding new capabilities to support the life sciences. Today's collaboration is the latest in a series of strategic partnerships to build greater value for our clients as we fulfill this mission."
Nippon Express added, "We are excited to partner with Cryoport Systems, a recognized leader in providing temperature-controlled supply chain solutions. Working together we can leverage each other's complementary strengths to meet the rapidly growing demand in the life sciences and biopharmaceutical industries for a complete supply chain solution."

Cryoport And NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership For Temperature-Controlled Supply Chain Services

CryoPort's CRYOPDP Expands U.S. Footprint With Acquisition Of Bluebird Express; Terms Not Disclosed

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is a 106.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $56.16 million which beat the analyst consensus estimate of $55.27 million by 1.60 percent. This is a 7.12 percent decrease over sales of $60.46 million the same period last year.

CryoPort Q3 EPS $(0.31), Inline, Sales $56.16M Beat $55.27M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3993903-1&amp;h=3129756054&amp;u=https%3A%2F%2Fcyrx.co%2F45pR23R&amp;a=Cryoport%2C+Inc.">Cryoport, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company has signed a new three-year supply chain solutions agreement with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3993903-1&amp;h=80195321&amp;u=https%3A%2F%2Fwww.monashivfgroup.com.au%2F&amp;a=Monash+IVF+Group+Limited">Monash IVF Group Limited</a>&nbsp;(ASX: MVF), a leading provider of assisted reproductive services, as well as specialist women's imaging and diagnostic services in Australia and Southeast Asia.
Founded in 1971, Monash IVF is a leader in the field of fertility services and one of the largest providers of assisted reproductive technologies (ART) and tertiary-level prenatal diagnostics in Australia and Southeast Asia. With more than 100 locations across Australia, Monash IVF has achieved many Australian and world firsts in the industry. Its operating businesses include Monash IVF, Repromed, Fertility Solutions and KL Fertility Centre. Through this multi-year agreement, Monash IVF and its operating businesses will utilize Cryoport's cryogenic logistics solutions and ISO-certified risk mitigation process for the delivery of patients' reproductive materials throughout Australia and internationally. Reproductive materials may be moved from one clinic to another due to costs, a patients' personal move, access to specific donor materials, for storage purposes and more.
"At Monash IVF, we pride ourselves on bringing together specialists, sonographers, scientists, nurses and counselors who are leaders in their respective fields to deliver the best patient outcomes," said Michael Knaap, CEO of Monash IVF. "It should come as no surprise that we are equally dedicated to guaranteeing our partners' commitment to excellence. Cryoport's expert team and world-class logistics capabilities will provide our patients with the ease of knowing that their reproductive materials are secure throughout the entire shipping process."
"Monash IVF is Australia's oldest IVF provider, having achieved the world's first IVF pregnancy more than 50 years ago," added Jerrell Shelton, CEO of Cryoport. "To this day, the company remains a prominent leader in the field of fertility services. By joining forces and bringing our solutions and expertise to Monash IVF, we have the opportunity to support many more individuals and families throughout Australia and Southeast Asia in their plans to become parents."

Contracts

Cryoport Inks New Multi-Year Supply Chain Solutions Agreement With Monash IVF

CryoPort Inc (CYRX) has released an update. Edward Zecchini has transitioned from the Board of Directors to become the Chief Digital & Technology O...

CryoPort Inc Strengthens Leadership and Updates Executive Agreements

CryoPort Q4 2023 Earnings Preview

Notable earnings after Tuesday's close

CryoPort GAAP EPS of -$1.31 misses by $0.98, revenue of $57.26M misses by $1.13M

Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript

In a report released today, David Larsen from BTIG maintained a Buy rating on CryoPort (CYRX – Research Report), with a price target of $20.00. Dav...

CryoPort's Growth Trajectory: Navigating Temporary Setbacks with Strategic Acquisitions and Biopharma Recovery

In a report released today, David Saxon from Needham reiterated a Buy rating on CryoPort (CYRX – Research Report), with a price target of $18.00. D...

CryoPort Endorsed with 'Buy' Rating Amid Robust Commercial Growth and Dominant C&GT Market Presence

Cryoport Tanks On Chilling Results And Bad Decisions

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on CryoPort (CYRX – Research Report) and The Middleby (MIDD – ...

Analysts Conflicted on These Industrial Goods Names: CryoPort (CYRX) and The Middleby (MIDD)

BSRTF

CORZ

FLNT

MIDD

WDOFF

Press Releases

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors

The Law Offices of Frank R. Cruz Continues Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors

Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award

Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies

Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies

Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF

Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express

Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services

Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals

ChromaDex

Cytek Biosciences

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share